Genetic factors contribute to the phenotype of drug response. We systematically analyzed all available pharmacogenetic data from Medline databases on the impact that genetic polymorphisms have on positive and adverse reactions to antidepressants and antipsychotics. Additionally, dose adjustments that would compensate for genetically caused differences in blood concentrations were calculated. To study pharmacokinetic effects, data for 36 antidepressants were screened. We found that for 20 of those, data on polymorphic CYP2D6 or CYP2C19 were found and that in 14 drugs such genetic variation would require at least doubling of the dose in extensive metabolizers in comparison to poor metabolizers. Data for 38 antipsychotics were examined: for 13 of those CYP2D6 and CYP2C19 genotype was of relevance. To study the effects of genetic variability on pharmacodynamic pathways, we reviewed 80 clinical studies on polymorphisms in candidate genes, but those did not for the most part reveal significant associations between neurotransmitter receptor and transporter genotypes and therapy response or adverse drug reactions. In addition associations found in one study could not be replicated in other studies. For this reason, it is not yet possible to translate pharmacogenetic parameters fully into therapeutic recommendations. At present, antidepressant and antipsychotic drug responses can best be explained as the combinatorial outcome of complex systems that interact at multiple levels. In spite of these limitations, combinations of polymorphisms in pharmacokinetic and pharmacodynamic pathways of relevance might contribute to identify genotypes associated with best and worst responders and they may also identify susceptibility to adverse drug reactions.
The need for predictive pharmacogenetics-based therapeutic recommendations
Major depressive disorder, schizophrenia, and related disorders are among the most important causes of death and disability worldwide. 1 These disorders are highly prevalent, chronic or recurrent conditions with a substantial impact on public health. Antidepressant drugs are the standard of care for clinical depression; likewise, antipsychotics are the standard treatment for schizophrenia. Despite the availability of a wide range of different drug classes, about 30-50% of patients will not respond sufficiently to acute treatment, regardless of the initial choice of standard psychiatric medication. [2] [3] [4] [5] For example, in randomized controlled trials in major depressive disorder, after 6-8 weeks, only 35-45% of the patients treated with standard doses of the most commonly prescribed antidepressants return to premorbid levels of functioning without any significant depressive symptoms. 6, 7 There is consequently a considerable need to increase efforts in maximizing clinical outcomes in major psychiatric disorders. The identification of genetic factors underlying drug response is among the most promising areas of research in molecular medicine.
Large genetic variability has been described in drug metabolism, in drug effects, and genetic modulators of the response to drug treatment. However, it is not yet possible to use genetic tools to identify an individual's likelihood of responding to a treatment and thereby to individualize drug therapy by choosing the best medication and dosage. While faster and more effective methods for genetic testing are being developed, the concept of formally using pharmacogenetics to guide therapy can only be clinical applicable when there is reliable ability to predict clinical outcomes. Blood typing for the A, B, O system may serve as an analogy of how specific therapeutic products are administered after being specifically guided by a laboratory genetic test. Similarly, specific clinical guidelines in psychopharmacology have to be developed to clarify in which situations and with which consequences the results of individual pharmacogenetic tests may be applicable for therapy.
This review covers methods for data extraction from pharmacogenetic studies and for aggregating such information into concise and usable therapeutic recommendations. This concept is nearly established with respect to polymorphisms in pharmacokinetic pathways, but use of genetic testing of neurotransmitter transporter and receptor variants for therapeutic decisions, is still incipient. Rapid advances in molecular analytical tools will soon allow very rapid and inexpensive genotyping; however, pharmacogenetics will only be used as a diagnostic tool in clinical practice, if precise and specific treatment options and guidelines based on genetic testing can be provided.
Methods of pharmacogenetics data extraction and dose calculation
Literature research Data on antidepressant and antipsychotic genotypedependent pharmacokinetics published in Medline and Embase databases were searched using word combinations of 'cytochrome', 'debrisoquine', 'sparteine', 'dextromethorphan', 'mephenytoin', 'polymorph*', 'metabolizer', 'ultrarapid', 'antidepressant', 'antipsychotic' in combination with 36 generic names of commonly used antidepressants and 38 antipsychotics. Data on therapeutic response and adverse drug reactions of antidepressants and antipsychotics in relation to genetic parameters were retrieved from current Medline using search combinations 'antidepressant', 'polymorphism', 'antipsychotic', 'genetic', 'response', 'tardive dyskinesia', and 'adverse drug reactions'. Studies on inherited susceptibility factors for depression and schizophrenia were not included, because the focus of this work was on the phenotype of drug response, not on the elucidation of the genetic basis of disease susceptibility. Data were classified according to gene polymorphisms studied, sample size, time interval for response measurement, clinical outcome parameters, and surrogate parameters (rating scales for response, documentation of adverse drug reactions).
With respect to pharmacokinetically relevant polymorphisms, only data from human studies with healthy volunteers or patients were included. Data on the in vitro biotransformation of antidepressants and antipsychotics have been reviewed elsewhere. [8] [9] [10] [11] [12] Studies were restricted to those providing data on effects of genetic polymorphisms in CYP2D6, CYP2C19, or CYP2C9. The functional impact of other polymorphisms in drug-metabolizing enzymes including CYP1A2, CYP2A6, CYP2B6, CYP3A4, -5, and -7 or phase-II enzymes in psychopharmacology was considered to be either too moderate or controversial.
The cytochrome P450 enzyme 1A2 partially catalyzes biotransformation of clozapine, olanzapine, and some other antipsychotics; 10 however, it remains questionable how much of the interindividual variability in CYP1A2 activity is explained by genetic polymorphisms. [13] [14] [15] Some data exist on higher drug concentrations and higher risks for tardive dyskinesia in schizophrenic patients who are smokers and carriers of CYP1A2 genotypes with reduced inducibility (C/A polymorphism at position 734 in intron 1 and G/A polymorphism at position À2964 in the 5 0 -flanking region of CYP1A2), but those results have not been fully replicated. [16] [17] [18] Polymorphisms in CYP2B6 might be relevant for the antidepressant bupropion, but the differences due to genotype are small. 19 Polymorphisms in the CYP3A enzyme family were not considered, since CYP3A4 genetic variants have little effects on function or are rare in most populations. 20 Whether or not the polymorphisms in CYP3A5 and CYP3A7 play a medically relevant role is questionable since expression levels are low and a psychotropic drug selectively metabolized by either CYP3A5 or CYP3A7, but not by CYP3A4, still remains to be identified. 21 Studies using CYP inhibiting substances such as quinidine to mimic poor metabolizer status were not included. Studies were classified based on whether they were conducted in patients or healthy volunteers, single or multiple dosage, existence of data on active metabolites/active moiety of the drug, sample size, and available pharmacokinetic parameters. For dose adjustments, dose-related pharmacokinetic parameters such as trough concentrations at steady state (C tss ), area under the concentration-time curve (AUC), or total drug clearance (Cl) were used. Data on metabolic ratios (MR) in urine or plasma could not be used since these parameters are not linearly correlated with dose.
As many psychotropic drugs are metabolized to equally active metabolites, 22 some studies provide data on both metabolite and parent drug, and thus the whole active moiety was taken into consideration. In Tables 2 and 3 , data of all studies are shown and the substances measured in the respective studies are indicated. In Figures 2-4 , dose adjustments calculated as the weighted mean from the single studies were depicted for each substance and data of the active moiety were taken if available.
Metabolic polymorphisms
Classification of metabolizer groups The homozygous carriers of two CYP2D6 genes coding for functional enzymes are termed extensive metabolizers (EM; genotypes: *1/*1, *1/*2, *2/*2) and carriers of one duplication allele (*2 Â 2 or *1 Â 2) plus one deficient allele (eg *3, *4; *5, *6) were also classified as extensive metabolizers. Heterozygous carriers of only one active allele were termed intermediate metabolizers and homozygous or compound homozygous carriers of two deficient alleles were termed poor metabolizers. Ultrarapid metabolizers identified by genotype were carriers of any combination of one CYP2D6*1 or one CYP2D6*2 gene duplication in combination with another active allele (genotypes: *2 Â 2/*1, *1 Â 2/*1). 23, 24 CYP2D6 alleles *9, *10, *17, and *41 were also classified as active alleles but with intermediate to low activity. 25 In Africans, the CYP2D6*17 allele is frequent and causes greatly decreased (but not deficient) enzyme activity. This has to be considered if genotyping is used to predict metabolic phenotype in African populations. 26 In Orientals, the CYP2D6*10 allele causing decreased (but not deficient) enzyme activity is prevalent with an allele frequency of about 50%. Heterozygous carriers of *10 may be in the higher activity range of the IM group and homozygous carriers (CYP2D6*10/*10) may be at the lower activity range. 27 The poor metabolizer genotype with two deficient alleles is very rarely found in Orientals (o1%); therefore, studies in Japanese, Chinese or Korean individuals are mostly focused on intermediate and extensive metabolizers of substrates of CYP2D6. Studies analyzing the impact of the CYP2D6*10 genotypes are marked by a number sign (#) in Table 2 , and for these studies PM genotype data are extrapolated from data in IMs and EMs.
For CYP2C19, the following classifications of metabolic phenotype based on genotype were made: extensive metabolizer: genotype *1/*1; intermediate: heterozygous carrier of one inactive CYP2C19 allele (*2, *3) and poor metabolizer as homozygous combination of two deficient CYP2C19 alleles. Most studies did not provide data on intermediate metabolizers. In these cases, a linear gene-dose relationship was assumed and a mean AUC of those of the PMs and EMs was used to calculate dose adjustments for heterozygous carriers of deficient alleles.
Phenotyping with debrisoquine or dextromethorphan for CYP2D6 and S-mephenytoin for CYP2C19 was considered equivalent to genotyping. Classification by phenotype was based on the usual urinary metabolic ratio antimodes of 12.6 for testing with debrisoquine and 0.3 for testing with dextromethorphan. 28, 29 Data calculation for dose adjustment To adapt doses according to genotypes, data on clearance (Cl), area under concentration-time curve (AUC) or trough concentrations at steady state (C tss ) in the respective genotype groups were used to calculate internal exposure to the drugs. It was assumed that the average dose recommended for the whole population can be regarded as the weighted mean of subpopulation-specific doses. 30 (Tables 1 and 2 ):
and
Then, Equations (2) and (3) can be substituted into (1): 
As explained above, in most studies from Asiatic populations only data on CYP2D6 EMs and IMs are available. For calculation of dose recommendations, a linear gene-dose effect was assumed and the AUC in PMs was estimated as follows:
For CYP2C19, genotype frequencies of approximately 3% PM, 27% IM and 70% EM as known in Caucasian populations were used. 32 The equation for CYP2C19 corresponding to Equation (1) would be ethnic groups other than Caucasians, it is advisible to calculate the dose adjustments based on the standard dose used in that population. Ethnic differences in the response to a drug are not only due to differences in the frequencies of drug metabolic enzyme polymorphisms, but also due to differences in nutrition, other lifestyle factors, and the effects of various other genotypes on the pharmacodynamic site of drug action.
Limitations of dose adjustments based on CYP2D6 or CYP2C19 genotype An approach using the principles of bioequivalence has been described above. However, drug concentration differences due to genotype are not exactly the same as drug concentration differences due to different preparations of a drug because the active metabolites also contribute to the overall drug effect or are responsible for adverse drug reactions. 22, 33 Whenever possible, we based dose adjustments on the active moiety of drug exposure consisting of parent drug and active metabolites if prevalent in considerable concentrations.
Many psychotropic drugs are administered as racemates and the enantiomers may undergo differential biotransformation, have different receptor binding profiles and different side effects, 34, 35 but pharmacologic activities of the specific enantiomers are frequently unknown in humans: enantiomers have been in most cases only tested in animals or in vitro. Therefore, dose recommendations might not be able to take the differential activity of enantiomers into account.
Some psychotropic drugs show saturation kinetics in the common dose-range. For clomipramine, desipramine, fluvoxamine, haloperidol, paroxetine, trimipramine, dose adjustments are only applicable in the dose ranges used in research studies, which is often much lower than clinical dosages.
Data from single dose experiments cannot be extrapolated to long-term drug therapy as saturation pharmacokinetics, irreversible enzyme blockade, or enzyme up-or downregulation might change the outcome under multiple dosing. [36] [37] [38] Enzyme inhibition by the substrate itself was described to convert genotypic extensive metabolizers of CYP2D6 substrates to phenotypically poor metabolizers in antidepressant drug therapy. [39] [40] [41] Drug target polymorphisms Data analysis We included all available studies concerning response to therapy and adverse drug reactions. We did not include studies on genetic polymorphisms as risk factors for the genetic susceptibility to mental illness. Essential parameters in this meta-analysis were sample size (power of the study), effect size and statistical significance. Effect size was either the odds ratio (if therapy response or adverse events were dichotomized) or the effect ratio (if response was presented on a continuous scale in the respective size). Effect ratio was the ratio of the response criterion in the group with the variant at risk divided by the response criterion in the complementary group. Funnel plots were used to assess for possible publication bias (Figures 5-7) . 42 Such funnel plots illustrate the relationship between sample size of clinical trials and the study outcome. From statistical theory, it is expected that the odds ratio or the effect ratio converging to the true values if sample size of studies becomes larger and individual study data should scatter randomly around the overall mean of all studies, unless there is selective publication.
Pharmacokinetic phase: dose adjustments based on polymorphisms in cytochrome P450 enzymes Examination of research on metabolism of 36 antidepressants and 38 antipsychotics was conducted (Table 1) . For 20 antidepressants, data on CYP2D6 or CYP2C19 polymorphisms from pharmacokinetic studies in humans were found.
For iprindole, isocarboxacid, setiptiline, and viloxazine, no data on polymorphic drug metabolism were found. Elimination mainly via conjugation reactions (glucuronidation, acetylation, sulfatation) and subsequent renal excretion was described for phenelzine and tranylcypromine, and elimination via renal excretion of the unchanged compound was described for milnacipran.
For several tricyclic antidepressants, no data on the specific enzymes involved in hydroxylation or demethylation reactions were available, and apparently the impact of genetic polymorphisms for biotransformation of these drugs has not been studied. However, structural similarity to other tricyclics such as imipramine implicates that CYP2D6 and CYP2C19 might be involved in metabolism of these tricyclics, as well.
Tianeptine as well as reboxetine seem to be mainly metabolized by CYP3A4 in humans and genetic polymorphisms of CYP2D6, CYP2C19 and CYP1A2 enzymes are unlikely to cause relevant pharmacokinetic variability of these antidepressants. 9 The new atypical antidepressant duloxetine is a potent inhibitor of CYP2D6 in vivo and a CYP2D6 substrate in vivo. 43 It therefore seems probable that CYP2D6 genetic polymorphisms have a major impact on elimination of this drug, but this has not yet been studied in detail.
CYP2D6 or CYP2C19 polymorphisms were studied for the metabolism of 13 antipsychotic drugs (Table  1) . Other elimination pathways than cytochrome P450 enzymes are important for following antipsychotics: sulpiride and amisulpride (renal excretion), raclopride (glucuronidation, sulfatation), zotepine (flavinmono-oxygenases involved). CYP3A4 is the main enzyme involved in the metabolism of bromperidole, iloperidone, perospirone, quetiapine, and ziprasidone. 8, 44 For chlorpromazine, remoxipride, and sertindole, only in vitro data exist on involvement of CYP2D6. 8 Remoxipride and sertindole were withdrawn from the market due to adverse drug reactions (aplastic anemia and arrhythmia). Melperone is described as potent inhibitor of CYP2D6 but studies on impact of CYP2D6 polymorphisms on melperone metabolism are not yet available. 45 Studies on polymorphic metabolism by CYP2D6 Table 2 summarizes all human studies found for antidepressants and antipsychotics: information on poor and extensive metabolizers of CYP2D6 are shown and percents of dose adjustments were calculated from AUC, Cl, or C tss as described above. There is good concordance of the quantitative effects on pharmacokinetic parameters among various studies.
Impact of CYP2D6 polymorphisms on dosing of antidepressants
Tricyclic antidepressants The group of tricyclic antidepressants undergoes similar biotransformation actions in the liver with CYP2D6 catalyzing hydroxylation reactions, [49] [50] [51] 68, 121, 122 whereas demethylation of the parent drug is mediated by CYP2C19. Both metabolites are pharmacologically active and the demethylated metabolites are partially tricyclic drugs by themselves such as nortriptyline and desipramine, which are desmethylmetabolites of amitriptyline and imipramine, respectively. For dose adjustments, the active drug moiety consisting of the sum of parent drug þ demethylated metabolite was used if available from the studies. The desmethyl-metabolite-drugs nortriptyline and desipramine are mainly hydroxylated to less active or inactive metabolites, 63, 121 in consequence, dose adjustments were calculated taking the parent drug alone.
Differences in the internal exposure to the drug (AUC) due to genotypes were mostly similar when comparing single-dose or multiple-dose studies ( Table 2) . Stereoselective metabolism by CYP2D6 was reported in trimipramine metabolism towards the less active L-trimipramine 68 and for doxepin, CYP2D6 polymorphisms had influence only on clearance of the less active E-isomer. 59 For these two tricyclics, dose adjustments should be based on the active drug compound (active enantiomers or isomer plus demethylated metabolite).
An extremely high clearance was described for a few CYP2D6 ultrarapid metabolizers from studies with nortriptyline and desipramine. For nortriptyline, one ultrarapid metabolizer carrying 13 active CYP2D6 genes was included, which caused the very high mean of clearance in this group. 61, 123 However, the 1-10% carriers of a CYP2D6 gene-amplification allele found in Caucasian populations usually carry only one gene duplication and should get moderately higher doses as calculated above and as illustrated in Figures 2 and 3 .
In Figure 1 , dose adjustments calculated from the data of Table 2 of all studies on tricyclic antidepressants and CYP2D6 polymorphisms are depicted in relation to the number of EMs or PMs studied. As can be seen in the figure, despite small sample sizes, different studies come to very similar results for dose adjustments. CYP2D6 PMs seem to be dosed correctly with approximately half of an average dose of tricyclic antidepressants.
Selective serotonin reuptake inhibitors Some selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine, fluvoxamine, and paroxetine are potent inhibitors of CYP2D6 activity. Therefore, multiple dosing causes decreased CYP2D6-mediated metabolism of the drugs themselves, and conversion from extensive to slow metabolizer phenotype and from ultrarapid to extensive metabolism was described. [124] [125] [126] [127] Unfortunately, these studies for fluoxetine and fluvoxamine describing conversion from higher to lower enzyme activity have studied the effect of enzyme inhibition only in one genotype group 40, 127 and could therefore not be used in our dose calculation approach.
Genotype-based dose adjustments might be necessary for paroxetine (Table 2 ), but less for fluoxetine and fluvoxamine; moreover, caution has to be paid to drug interactions. These drugs are strong inhibitors of CYP2D6, and therefore, differences in pharmacogenetic parameters are substantially decreasing under multiple dosing conditions 72, 75 (Table 2 ). For paroxetine, undetectable drug concentrations are described in one ultrarapid metabolizer carrying at least three functional CYP2D6 genes. For sertraline and citalopram, no influence of CYP2D6 polymorphisms on pharmacokinetic parameters was detected.
Other antidepressants For other antidepressants (bupropion, maprotiline, mianserin, mirtazapine, moclobemide, nefazodone, reboxetine, venlafaxine), no general assessment on polymorphic drug metabolism can be made.
Bupropion is a substrate of CYP2B6 and apparently not influenced by CYP2D6 polymorphisms. 76 In about 100 subjects, no major effects of CYP2B6 genotypes on bupropion pharmacokinetics were identified. 19 There are contradictory data regarding the effects of CYP2D6 polymorphisms on metabolism of the tetracyclic antidepressant maprotiline: while in a patient group receiving monotherapy with 150 mg maprotiline, no differences in steady-state concentrations were detected due to the debrisoquine metabolizer status, 77 a study with healthy volunteers receiving 100 mg maprotiline over 7 days, revealed differences similar to those detected in tricyclics. 78 For mianserin, CYP2D6 mediates enantioselective hydroxylation of the more active S-( þ ) mianserin. For dose adjustments, the sum of S-( þ )-mianserin and the active desmethylmianserin was taken ( Table 2) .
For the racemic drug mirtazapine, S-( þ )-mirtazapine clearance significantly depends from CYP2D6 genotype, but no CYP2D6 effect on R-(À)-mirtazapine clearance was found.
128 Achiral analysis did not reveal CYP2D6 genotype-related differences. 82 Further clinical studies are warranted on the impact of CYP2D6 on mirtazapine clinical effects and adverse events, which differ between both enantiomers.
For moclobemide, nefazodone, reboxetine, and trazodone, CYP2D6 polymorphisms do not seem to have a major influence on metabolism in humans. 37, [83] [84] [85] [86] 129, 130 Venlafaxine is a chiral drug with both enantiomers transformed by CYP2D6 to the equipotent O-desmethyl-venlafaxine. 88, 90, 131 Thus, the active drug moiety, sum of parent drug and metabolite is not much changed by the CYP2D6 genotype. However, a higher risk for cardiotoxic events and severe arrhythmia was reported in four patients admitted to a cardiologic unit who all were PMs, according to CYP2D6 function. 87 Dose adjustments based on parent drug alone would lead to 60% reduction of the average dose for PMs. Figure 2 shows the differential doses of antidepressants needed because of polymorphisms of CYP2D6 as the weighted mean (weighted according to the sample sizes in the studies) of single-study data given in Table 2 . Dose adjustments are given for poor, intermediate, extensive, and ultrarapid (UM) metabolizers of CYP2D6. For the UM group, extrapolation was made assuming a linear gene-dose effect according to the calculation methods given above. If possible, data on active moiety of the drug (sum of parent drug and active metabolites) after multiple dosing were taken and if more studies exist, mean dose adjustments were calculated. The figure shows that the amount of dose adjustment varies for substrate to substrate, and that clinically relevant differences in dosages are supported by existing data. 
Impact of CYP2D6 polymorphisms on dosing of antipsychotics The influence of CYP2D6 polymorphisms on antipsychotic drug metabolism was studied in humans for aripiprazole, clozapine, flupentixol, haloperidol, levomepromazine, olanzapine, perazine, perphenazine, pimozide, risperidone, thioridazine, and zuclopenthixol. Differences in pharmacokinetic parameters resulting in dose adjustments are depicted in Table 2 , and dose recommendations according to the results from the studies in each substance are expressed in Figure 3 .
The recently released antipsychotic drug aripiprazole was studied for polymorphic CYP2D6 metabolism prior to marketing, and 60% higher exposure to the total active moieties (parent drug and dehydroaripiprazole) was detected in PMs compared to EMs (aripiprazole drug information) ( Table 2) . Similar dose variations were detected for flupentixol as well as for perazine in a naturalistic study with schizophrenic patients receiving different doses. 92 For thioridazine, a recent study within patients reports a large difference in pharmacokinetics resulting in 30% of the average dose in PMs, 116 which corresponds to the data from a study in healthy volunteers administering single doses, 114 but is in contrast to another study in patients where smaller differences were found. 115 For dose recommendations, the weighted mean of the dose adjustment was taken from the two studies in patients (with multiple doses) according to the number of PMs (Figure 3 ).
For haloperidol, differences in drug metabolism lead to 60-70% of the average dose for PMs 94, 96 and two studies did not report significant differences at all. 93, 95 However, a significant higher risk for extrapyramidal side effects in PMs was observed, probably due to higher levels of reduced haloperidol. Patients with UM genotype had the worst clinical outcome measured by the positive and negative symptoms scale. 96 For perphenazine, thioridazine, and zuclopenthixol, pharmacokinetic differences due to CYP2D6 genotype decreased under steady state compared to single-dose studies (30-40% decrease with PM single dose, and 60-70% with multiple dosing) and risperidone with 20% for PMs according to single dose and no significant differences for multiple doses due to an active CYP2D6-generated metabolite.
For olanzapine, a single-dose study in healthy volunteers failed to show CYP2D6-mediated differences, whereas in a patient study, steady-state concentrations differed according to the CYP2D6 genotype. 105 Our own data indicated the same trend (Kirchheiner et al., unpublished) .
For zuclopenthixol, the only study evaluating depot medication and CYP2D6 genotype revealed that CYP2D6 PMs should get only 70% of an average dose. 120 Consequently, particularly at the beginning of antipsychotic treatment, knowledge about the poor 
Impact of CYP2C19 polymorphisms
When compared to CYP2D6 polymorphisms, substantially fewer studies were conducted evaluating CYP2C19-mediated differences in drug metabolism (Table 3) . Since CYP2C19 poor metabolizers are more frequent in Asiatic populations (13-23% in contrast to 2-5% in Caucasians 132, 133 ), several studies of Table  3 were conducted in Japanese individuals.
In general, CYP2C19 seems to be involved in demethylation biotransformation reactions of tricyclic antidepressants as was shown for amitriptyline, clomipramine, doxepin, imipramine, and trimipramine (Table 3 and Figure 4 ). For these drugs, PMs seem to be adequately adjusted with about 60% of the average dose and EMs with 110%. The same dose adjustments seem to be adequate for moclobemide and citalopram.
Impact of CYP2C9
Carriers of the alleles CYP2C9*2 and *3 have lower enzyme activity compared with carriers of the wildtype allele (CYP2C9*1), and a CYP2C9*4 allele with completely deficient enzyme activity was found in a single African-American subject.
143 CYP2C9*2 and *3 alleles have frequencies of about 12 and 8% in Caucasians (our own data on 1010 Caucasians), but CYP2C9*2 is rare in Asian populations.
All currently existing data show only a minor contribution of CYP2C9 polymorphisms for interindividual pharmacokinetic variability of tricyclic antidepressants: data on amitriptyline are based on in vitro studies only, a small difference in kinetics between carriers of CYP2C9*1/*1 and *3/*3 was shown for trimipramine and doxepin. 59, 67 Clinical impact of pharmacogenetic testing for polymorphic drug metabolism Although differences in the pharmacokinetic parameters due to polymorphic metabolism are relatively well characterized with a surprisingly good betweenstudy concordance (Tables 2 and 3 , and Figure 1 ), the impact of those variations on therapeutic outcomes and incidence and severity of adverse drug reactions are not as well documented. Few studies provide quantitative data on adverse drug reactions. 49 induced seizures was reported in relation to CYP2D6 activity 145 and several studies showed a relationship between extrapyramidal side effects of antipsychotic drugs and CYP2D6 polymorphisms. 96, [146] [147] [148] [149] [150] [151] [152] [153] [154] [155] [156] However, compared to the large efforts made to evaluate pharmacokinetic differences due to CYP polymorphisms, few prospective studies on benefit of phenotyping or genotyping for therapeutic outcome have been conducted so far. It was estimated from retrospective assessments that patients with psychiatric disorders Table 2 . If data on active drug moiety (consisting on active principle metabolite þ parent drug of active enantiomers of a racemic drug) were given, dose recommendations were based on these data only (other studies not providing so detailed information were not incorporated). If more than one study was integrated, the weighted mean for the dose adjustment was taken according to the number of poor metabolizers in each study. Data on mirtazapine, moclobemide, fluoxetine, and maprotiline were not shown in the figure, since no dose adjustment based on CYP2D6 can be recommended at present. Therapeutic implications from pharmacogenetics J Kirchheiner et al who are poor or ultrarapid metabolizer of CYP2D6 cost US$ 4000-6000 more per year than extensive metabolizers. 157, 158 The next step is to perform prospective controlled analyses on the benefit of genotyping in drug therapy: one group should receive therapeutic recommendations according to genotype, whereas the other group should be treated as usual.
Dose reduction might take place by prolongation of the dosing interval and/or by reducing the single dose. Due to first-pass metabolism, dose adjustments may be smaller in i.v. than in oral doses as shown recently by a study on trimipramine. 159 However, the validity of these calculated dose adaptations ( Figures  2-4) for dose recommendations remains to be tested.
Pharmacodynamics: polymorphisms in neurotransmitter transporters, receptors, and other drug targets
As pharmacokinetic factors explain only a small part of the variability in therapeutic response, efforts have to concentrate on variations within target molecules in the brain. Thus far, mostly dopaminergic and serotoninergic receptors and transporters have been studied in patients as predictors of the response to psychotropic drug therapy (Table 4) . Systematic exploration of other transmitter systems, of downstream intracellular signaling molecules, of neurotrophic factors and their receptors is a major goal of the next few years.
Serotoninergic system

Serotonin transporter
Role in antidepressant drug therapy The molecular mechanism of antidepressant drug action involves inhibition of the neuronal serotonin transporter. One apparently functional polymorphism in the 5 0 -upstream regulatory region of this gene is a 44-base pair (bp) insertion/deletion resulting in a long (l) and a short (s) variant, the latter resulting in two-fold decreased expression and transport activity in vitro. 191, 192 Several studies have reported a better response to SSRIs in individuals carrying two (l)-alleles of the 44-bp insertion/deletion polymorphism in the regulatory region of the serotonin transporter (SERT). 168, 169, [171] [172] [173] [174] [175] 193 Two studies had contradictory results. 165, 170 This discrepancy might be due to ethnic differences: the (s)-allele frequency is much higher in Orientals than in Caucasians (79 vs 42%), 194 and both studies showing an association of the (s) allele with better response were conducted in Oriental patients. However, Yu et al, 169 who also studied an Asian population, found data similar to the European studies. Thus, ethnicity does not provide a clear explanation of the discrepancies and further studies are required for confirmation.
Increased circulating prolactin levels, used as a surrogate parameter of antidepressant drug action, were reported to be higher in individuals carrying the (l)-allele. 166, 167 In Figure 5 , effect size of the studies is depicted in relation to sample size. One would expect from such plots a symmetric convergence of the effect towards the overall mean with increasing sample size. None of the authors has given a specific solution how the knowledge about differences in response depending on SERT genotype should be used in psychiatric practice. A rational approach would be to prefer primarily noradrenergic agents or tricyclics in carriers of the s/s genotype; however, this requires confirmation in a clinical study.
Another polymorphism is located in intron 2 of the SERT gene. It is a variable number of tandem repeats (VNTR) polymorphism resulting in three frequent alleles containing 9, 10, and 12 copies of the VNTR element. The VNTR was shown to act as strong positive transcriptional regulatory element for SERT in mouse embryonic rostral hindbrain and the (l)-allele containing 12 copies had the strongest Therapeutic implications from pharmacogenetics J Kirchheiner et al transcriptional inducing ability. 195 Two studies assessed the predictive value on antidepressant response of this VNTR, but an initially described association with an odds ratio of 32 of the (l) 12 allele with better response to SSRIs 165 was not replicated. 164 Studies on the association of adverse drug reactions and SERT polymorphisms show that there is a positive association with the risk of switching to mania, but no correlation to antidepressant-caused nausea. 196, 197 Fluoxetine-induced insomnia appeared to be greater in carriers of the s/s genotype. 198 Role in antipsychotic drug therapy Newer antipsychotics appear to exert their effects partially through the serotoninergic systems making the SERT a logical candidate gene for prediction of antipsychotic drug response. One study showed a better response to clozapine in carriers of the (l)-allele (Table 5 ). For various typical antipsychotics, in 684 patients, no differences in drug response were observed in relation to SERT genotype. 199 Adverse effects of antipsychotics have also been related to SERT polymorphisms. A slightly higher frequency of the SERT l/l genotype was observed in patients suffering from tardive dyskinesia with an odds ratio of 1.9; however, differences were not statistically significant. 200 Clozapine-induced weight gain was not associated with the SERT promoter polymorphism either. 201 
Serotonin receptors
Role in antidepressant drug therapy Serotonin (5-HT) receptor genes are further candidate genes for the prediction of antidepressant response. Several studies have shown that paroxetine induces downregulation of the 5-HT 2A receptor, 202, 203 which has been reported to be overexpressed in depressed patients. 204 Three polymorphisms have been described in the 5-HT 2A gene: a silent point mutation 102T4C that is completely linked to a À1438G4A promoter polymorphism, and a polymorphism in the coding region causing a His452Tyr amino-acid substitution. A better treatment response to antidepressants in patients with one or two C-alleles of the 102T4C polymorphism was reported as compared to T/T homozygotes. 160 In contrast, no significant association between the completely linked À1438G4A polymorphism and therapeutic response to fluvoxamine was observed. 162 A severe adverse drug effect related to the serotonin system is the serotonin syndrome characterized by serotonin-related side effects with symptoms such as mental status changes, agitation, myoclonus, hyperreflexia, tremor, and diarrhea. 205 Impaired drug metabolism of serotonergic drugs caused by genetic deficiency of drug-metabolizing enzyme activity, as well as genetic factors in serotonergic neurotransmission, might be involved, but serotonin receptor polymorphisms have not been systematically analyzed in this context.
Role in antipsychotic drug therapy Even though the mechanisms of action of clozapine are incompletely elucidated, it appears that in comparison to typical neuroleptics, this atypical antipsychotic drug has more effects at the level of serotoninergic systems and less on dopaminergic systems. 206 Effect size: If data available, odds ratio was calculated or taken from the studies or the ratios of the decrease in rating scores (in%) or mean end rating score * were taken. ** in one case, visual analogue scales (VAS) measuring mood were used and effect size was expressed as increase in VAS. a P-value is based on s/s genotype group compared to both, the l/l and the s/l group together. NS ¼ nonsignificant. Therapeutic implications from pharmacogenetics J Kirchheiner et al therapeutic response to clozapine. In Figure 6 , studies on serotonin receptor polymorphisms as predictors of clozapine response are depicted in relation to effect size and sample sizes. In cases where Z3 studies on the same polymorphism have been performed, studies are ordered by sample size. The true impact of a polymorphism as a predictor for response is dependent, if this result is reproduced in several independent studies. Nevertheless, a possibility of publication bias has to be considered. A first hint for possible publication bias is deviation from the theoretically expected pattern in the funnel plots where studies should converge with increasing sample size. The weighted mean of the odds ratios of all studies on 5-HT 2A receptor genotypes was 1.7, thus predicting only a minor influence of this gene on clozapine response (Table 5) . Two studies on antipsychotic response to various antipsychotics other than clozapine did not show any correlation to 5-HT 2A receptor genotype. 240, 241 For 5-HT receptor subtype 2C, one study reported significant better clozapine response in individuals carrying the Ser allele of the Cys23Ser variant, 229 but subsequent studies failed to reproduce this observation. 220, 225, 230, 231 The 5-HT receptor variants have also been studied as predictors of antipsychotic drug adverse events including tardive dyskinesia, weight gain, and malignant neuroleptic syndrome, but mostly without significant results (Table 6 ).
Serotonin biosynthesis
Tryptophan hydroxylase is the rate-limiting enzyme of serotonin biosynthesis. 185, 186 One polymorphism (218A4C) located in a possible transcription factorbinding site may influence gene expression. 280 Significant associations with response to SSRIs were reported in individuals carrying the C variant of the A218C polymorphism. 185, 186 Recently, it has been elucidated that tryptophan hydroxylase expressed in the brain is coded by a gene (TPH2) different from that coding for peripherally expressed tryptophan hydroxylase (TPH1) 281 and animals in which TPH1 was knocked out had normal central tryptophan hydroxylase. Thus, the older polymorphisms data will have to be reanalyzed and an analysis of the TPH2 gene regarding medically relevant polymorphisms has to be performed. Regeneration of serotonin from 5-methoxytryptamine is mediated by polymorphic human CYP2D6; this drug-metabolizing enzyme is therefore also directly involved in serotonin homeostasis. 282 
Dopaminergic system
Dopamine receptors Dopamine receptors are classified according to their signal transduction pathways and sequence homology into the dopamine D1-like receptors (DRD1 and DRD5) and the dopamine D2-like receptors (DRD2, Figure 5 Impact of the SERT promoter 44-bp insertion/deletion polymorphism on the response to antidepressant medication. The odds ratios to respond to medication or effect ratios (ratio of responders with the l/l genotype over responders with other genotypes) are shown. If data were available, 95% confidence limites of the odds ratios were calculated and shown as horizontal lines. In such plots, the between-study variation should be as smaller as larger the sample size of the studies is. In addition, one expects that the scatter is symmetric around the common mean of all studies and asymmetry suggests publication bias.
Therapeutic implications from pharmacogenetics J Kirchheiner et al DRD3, and DRD4). Numerous polymorphisms have been described in all five receptors, 283, 284 but functional effects of most variants appear to be moderate. Variants resulting in completely deficient expression of DRD4 285 are very rare.
Role in antidepressant drug therapy Dopamine receptor genes might be less involved in antidepressant drug action, and so far, all studies resulted in odds ratios around 1 when testing the predictive value for antidepressant treatment response of dopamine receptor variants (Table 4) .
Role in antipsychotic drug therapy For dopamine receptor D2 (DRD2), two alleles A1 and A2 exist, of which allele A1 appeared to be associated with lower dopamine D2 receptor density in the brain and with diminished dopaminergic activity. 286, 287 However, data on the medical impact of these polymorphisms are controversial. Three amino-acid substitutions in the DRD2 are apparently functionally relevant 288 but these are rare, and conclusive clinical data are missing. Numerous other noncoding polymorphisms have been identified including two promoter polymorphisms (À241A4G and deletion À141C) but again, consistent data indicating a clinical impact are missing (Table 6) .
One recently performed meta-analysis on pharmacogenetics of tardive dyskinesia involved data from 780 patients from different populations (mostly Caucasian, but also African American and Ashkenazi) confirmed contribution of the dopamine receptor D3 (DRD3) Ser9Gly polymorphism with an odds ratio of 1.33 for carriers of the Gly variant; 252 however, in epidemiology, such small odds ratios are usually interpreted with caution. In Figure 7 , the odds ratio or effect sizes of the studies on the role of the DRD3 Ser9Gly polymorphism in tardive dyskinesia are depicted in relation to sample sizes. As illustrated in Figure 7 , the biggest effects were seen in the small studies and these effects were apparently not replicated in the larger studies. One explanation for this trend may be publication bias meaning that small studies with the opposite effect might also exist but have never been submitted for publication. 42 Dopamine D4 receptor (DRD4) polymorphisms have been studied as predictors of the response to the DRD4 ligand clozapine, but the results on a 16-amino-acid VNTR polymorphism were contradictory (Table 5) . [214] [215] [216] [217] [218] For typical (ie predominantly dopamine D-2 antagonistic) antipsychotics, only few studies were found on dopamine receptor genes (DRD2, DRD3, and DRD4). 210, [289] [290] [291] [292] [293] Most results were negative findings for response prediction. One study observed a slight over-representation of the DRD3 Ser9Gly amino-acid exchange (allele *2) in patients with poor response to antipsychotics, particularly in the non-Ashkenazi, Israeli schizophrenics. Odds ratio or effect ratio Scharfetter, 1999 Malhotra, 1998
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Norepinephrinergic system
Antidepressant efficacy is mediated not only by serotonin reuptake inhibition, but also by inhibition of the norepinephrine uptake. Norepinephrine reuptake inhibitors (NRIs) with variable selectivity are desipramine, lofepramine, viloxazine, maprotiline, oxaprotiline, and reboxetine. Several genetic variants have been identified in the human norepinephrine transporter gene; however, no association has been found so far between those polymorphisms and either bipolar disorder and schizophrenia. 294 It has not yet been studied if genetic polymorphisms in the norepinephrine transporter gene have influence on antidepressant drug response especially of the NRIs.
Candidate genes beyond the neurotransmitter axes
Antidepressant response
Associations with response to various antidepressant drugs were observed with the ACE 287-bp insertion/ deletion polymorphism, 176, 177 with the G-protein b3 subunit (GNB3). 182 Both genes play an important role in regulation of blood pressure, and there is a wellknown relationship between depression and cardiovascular disease. In turn, depression is a major risk factor for the development of coronary artery disease. In fact, it was shown recently by the authors, that the same allelic combination of ACE and GNB3 that have Ins/Del, Insertion/Deletion; 5 0 -UTR, 5 0 untranslated region. Scale: Rating scale used for response assessment: BPRS: brief psychiatric rating scale; CGI: clinical global impression scale; clinical impression: subjective clinical impression, without validated rating scale; GAS: global assessment scale; Time: time until response was defined. Effect size: If data available, odds ratio was calculated or taken from the studies. Unless, mean percent decrease in rating score or mean end rating score was taken. a In one study, mean absolute decrease in BPRS was given, since data on BPRS baseline were not available. Sign.: statistical significance (P-value). NS ¼ nonsignificant. 295 increase the vulnerability for depressive disorder. 296 The reason why most genetic variability within pharmacodynamic elements did not turn out to be highly predictive of favorable antidepressant treatment response might be that most studies focused on short-time effects of antidepressants such as changes in the serotonin-or noradrenaline-pathways. There is growing evidence that long-term antidepressant treatment enhances structural changes in neuroplasticity, and genes involved in neurotrophic signaling cascades, might act as antidepressant targets. 297 Future studies on genetic variability in antidepressant treatment response should focus on these systems, which in fact could be the common final pathway of different antidepressant strategies (irrespective of whether the drug used is primarily serotonergic or noradrenergic).
Antipsychotic response
Methylenetetrahydrofolate reductase (MTHFR) gene was studied in relation to antipsychotic drug therapy. 298 A missense mutation (677C4T) in the MTHFR gene was previously found to be associated with schizophrenia, 299 and a significant over-representation of the T allele in responders to antipsychotic therapy was found compared to nonresponders. Increased risk incarriers of DRD3 Gly/Gly Figure 7 Impact of the DRD3 Ser9Gly polymorphism for the risk to develop tardive dyskinesia during treatment with typical antipsychotics. The squares indicate the risk of carriers of the Gly/Gly genotype to develop tardive dyskinesia and the horizontal lines depict the 95% confidence intervals of these odds ratios. Although some studies with small sample size indicated a relevant impact of this DRD3 polymorphism, a review of all published studies does not indicate that the DRD3 polymorphism predicts tardive dyskinesia.
Catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO) enzymes are involved in metabolic inactivation of several neurotransmitters. Within the COMT gene, a G to A transition at codon 158 resulting in a Val158Met amino-acid exchange is responsible for 3-4-fold lower enzyme activity in Met/Met carriers compared to wild type. 300 For the MAO gene, a VNTR located in the upstream regulatory region was described to affect enzyme activity with lower activity in carriers of only three repeat elements in comparison to four. 301 Both functional polymorphisms were studied with regard to antipsychotic drug response, and the Met/Met genotype of the COMT gene was found to be associated with nonresponse to at least two antipsychotic drugs. The MAO gene promoter polymorphism showed an additional synergistic effect with a six-fold higher risk to be a nonresponder found in patients with genotypes predicting low activity of both enzymes than in patients with the wild-type genotype combination (COMT Met/Met and MAO 3/3 vs COMT Val/Val and MAO 4/4, odds ratio 6.1). 302 BDNF is involved in the neurodevelopment of dopaminergic-related systems. A dinucleotide repeat polymorphism is located 1040 bp upstream of the transcriptional site. 303 Allele distribution differed significantly in treatment-responding patients compared to refractory patients with an excess of (l)-alleles (172-176 bp) in the treatment responders. 304 Another polymorphism is located in the coding region and causes a Val166Met amino-acid substitution. In human subjects, the Met allele was associated with poorer episodic memory, and abnormal hippocampal activation. 305 The response to clozapine was studied in patients with regard to the Val166Met polymorphism but no association was found. 238 Polymorphisms in free radical detoxification might be particularly relevant for adverse events caused by haloperidol, which has reactive metabolites. An association of a polymorphism in manganese superoxide dismutase (SOD2) was found to be associated with tardive dyskinesia, 265 but replication failed. 266 Hypersalivation is a common side effect of clozapine, which might be caused by its b2-adrenoceptorblocking effects. 306 Thus, genetic polymorphisms within the b2-adrenoceptor gene might be associated with altered susceptibility to hypersalivation; however, no association has been observed so far. 208 There are several additional adverse drug reactions, for which susceptibility caused by genetic mechanisms are not yet elucidated. A variety of psychotropic drugs are associated with cardiac side effects, in particular with iatrogenic prolongation of the QT interval of the electrocardiogram, which in turn is associated with torsade-de-pointes arrhythmia. Tricyclic antidepressants, such as imipramine and amitriptyline, and phenothiazine antipsychotics, such as thioridazine, inhibit cardiac potassium channels. 307 Individual risk for drug-induced prolongation of the QT interval was shown to be related to genetic variants in genes encoding cardiac K þ -channels, such as the HERG gene encoding for a K þ channel subunit. 308 Several recently published studies on schizophrenia focus on susceptibility genes for schizophrenia, which have shared effects on synapses, such as glutamatergic, GABAergic, cholinergic, and monoaminergic synapses. 309 Polymorphisms in these genes (eg neuregulin, dysbindin, COMT, D-amino acid oxides (DAAO), regulator of G-protein signaling 4 (RGS4), and proline dehydrogenase (PRODH) may be candidates for prediction of antipsychotic therapeutic response, and will certainly be addressed in future studies.
Integrated multigene and multifactorial approaches
Promising efforts have been made to test for the best predictive value of combinations of polymorphisms in context of genetic prediction of response to clozapine. A set of six from 19 genetic polymorphisms was extracted showing the strongest association with clozapine response in a sample of 200 patients; 310 however, the exciting finding of 76% success in the prediction of clozapine response could not be replicated by others in a sample of 163 schizophrenic patients. 225 This illustrates the major problem of type I error adjustment in pharmacogenomic studies. Usually, it is a rational and necessary approach to consider multiple candidate genes and to consider their gene-gene and gene-environment interactions, but this exploratory approach results in substantial increases in the type I error.
As drug response is just as complex a phenotype as disease susceptibility, it is probable that genetic variability will derive not only from genotypes in the translated gene regions, but also from variability in gene expression and regulation. Genetic mechanisms on the level of drug metabolism and transport as well as in drug target structures such as neurotransmitter receptors and transporter molecules have to be systematically studied for their predictive value in terms of antidepressant drug response. This is a necessary foundation for the develop ment of clearcut therapeutic strategies. Individualized medicine is the overall goal of pharmacogenetic research. A systematic pharmacogenomic approach for optimization of antidepressant drug treatment is based on several levels: (1) identifying and validating the candidate genes involved in drug response, (2) developing a commercially viable pharmacogenetic test system for bedside-testing of patients' individual response profiles, and (3) providing guidelines for pharmacogenetic-based individualized drug therapy in the form of therapeutic strategy flow-charts and genotypic specific dose recommendations.
Conclusions
Pharmacogenetic knowledge will only be translated into daily clinical decision-making when it becomes Therapeutic implications from pharmacogenetics J Kirchheiner et al scientifically possible to provide relatively specific therapeutic recommendations. Therefore, this review intended to integrate pharmacogenetic results from clinical studies on drug response and pharmacokinetic variability into dose adjustments and therapeutic strategies. In terms of pharmacokinetic variability, quantitative dose adjustments based on genotypes can already be calculated for many antidepressants and antipsychotics. However, the actual outcome and benefit of pharmacogenetic individualization of drug therapy will have to be supported by future prospective studies, leading to dose recommendations that will then have to be validated. The pharmacodynamic aspects of psychotropic drug action, including the functional consequences of polymorphisms in neurotransmitter receptors, transporters, and molecules involved in signal transduction, cannot yet be easily translated into treatment recommendations. This is partly due to difficulties in replication of findings from association studies in prospective trials from diverse populations, and also might be due to the key problem of multigenetic influences. Rather than large effects given by single polymorphisms, multigenic interactions and geneenvironment interactions will have to be considered. Therefore, in the future, haplotype analyses and multigenetic analyses with sufficient power (adequate sample size and high quality of phenotypic data) might reveal the genotypes that predict clinical responses, including susceptibility to adverse drug reactions. We are optimistic that progress in this field will integrate excellence in clinical research and phenotypic characterization, genomic science, and bioinformatics to yield in the not-too-distant future a body of reliable data that will eventually guide clinical pharmacology and medical practice.
